Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Nicola C. Day; Subramanya Kumar; Gerard Criner; Mark Dransfield; David M. G. Halpin; MeiLan K. Han; C. Elaine Jones; Morrys C. Kaisermann; Sally Kilbride; Peter Lange; David A. Lomas; Neil Martin; Fernando J. Martinez; Dave Singh; Robert Wise; David A. Lipson

doi:10.1186/s12931-020-01398-w

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Nicola C. Day, Subramanya Kumar, Gerard Criner, Mark Dransfield, David M. G. Halpin, MeiLan K. Han, C. Elaine Jones, Morrys C. Kaisermann, Sally Kilbride, Peter Lange, David A. Lomas, Neil Martin, Fernando J. Martinez, Dave Singh, Robert Wise, David A. Lipson

Section of Epidemiology

Research output: Contribution to journal › Journal article › Research › peer-review

11 Citations (Scopus)

76 Downloads (Pure)

Original language	English
Journal	Respiratory research
Volume	21
Number of pages	12
ISSN	1465-9921
DOIs	https://doi.org/10.1186/s12931-020-01398-w
Publication status	Published - 2020

Keywords

COPD
Triple therapy
LAMA/LABA
ICS/LABA
Cardiovascular safety

Access to Document

10.1186/s12931-020-01398-wLicence: CC BY

Single-inhaler triple therapy fluticasone furoateFinal published version, 800 KBLicence: CC BY

Cite this

Day, N. C., Kumar, S., Criner, G., Dransfield, M., Halpin, D. M. G., Han, M. K., Jones, C. E., Kaisermann, M. C., Kilbride, S., Lange, P., Lomas, D. A., Martin, N., Martinez, F. J., Singh, D., Wise, R., & Lipson, D. A. (2020). Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respiratory research, 21. https://doi.org/10.1186/s12931-020-01398-w

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD : results on cardiovascular safety from the IMPACT trial. / Day, Nicola C.; Kumar, Subramanya; Criner, Gerard; Dransfield, Mark; Halpin, David M. G.; Han, MeiLan K.; Jones, C. Elaine; Kaisermann, Morrys C.; Kilbride, Sally; Lange, Peter; Lomas, David A.; Martin, Neil; Martinez, Fernando J.; Singh, Dave; Wise, Robert; Lipson, David A.

In: Respiratory research, Vol. 21, 2020.

Research output: Contribution to journal › Journal article › Research › peer-review

Day, NC, Kumar, S, Criner, G, Dransfield, M, Halpin, DMG, Han, MK, Jones, CE, Kaisermann, MC, Kilbride, S, Lange, P, Lomas, DA, Martin, N, Martinez, FJ, Singh, D, Wise, R & Lipson, DA 2020, 'Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial', Respiratory research, vol. 21. https://doi.org/10.1186/s12931-020-01398-w

Day, Nicola C. ; Kumar, Subramanya ; Criner, Gerard ; Dransfield, Mark ; Halpin, David M. G. ; Han, MeiLan K. ; Jones, C. Elaine ; Kaisermann, Morrys C. ; Kilbride, Sally ; Lange, Peter ; Lomas, David A. ; Martin, Neil ; Martinez, Fernando J. ; Singh, Dave ; Wise, Robert ; Lipson, David A. / Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD : results on cardiovascular safety from the IMPACT trial. In: Respiratory research. 2020 ; Vol. 21.

@article{50a4bc21b36249e9a44371ea901bad9e,

title = "Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial",

keywords = "COPD, Triple therapy, LAMA/LABA, ICS/LABA, Cardiovascular safety",

author = "Day, {Nicola C.} and Subramanya Kumar and Gerard Criner and Mark Dransfield and Halpin, {David M. G.} and Han, {MeiLan K.} and Jones, {C. Elaine} and Kaisermann, {Morrys C.} and Sally Kilbride and Peter Lange and Lomas, {David A.} and Neil Martin and Martinez, {Fernando J.} and Dave Singh and Robert Wise and Lipson, {David A.}",

year = "2020",

doi = "10.1186/s12931-020-01398-w",

language = "English",

volume = "21",

journal = "Respiratory Research (Print)",

issn = "1465-9921",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD

T2 - results on cardiovascular safety from the IMPACT trial

AU - Day, Nicola C.

AU - Kumar, Subramanya

AU - Criner, Gerard

AU - Dransfield, Mark

AU - Halpin, David M. G.

AU - Han, MeiLan K.

AU - Jones, C. Elaine

AU - Kaisermann, Morrys C.

AU - Kilbride, Sally

AU - Lange, Peter

AU - Lomas, David A.

AU - Martin, Neil

AU - Martinez, Fernando J.

AU - Singh, Dave

AU - Wise, Robert

AU - Lipson, David A.

PY - 2020

Y1 - 2020

KW - COPD

KW - Triple therapy

KW - LAMA/LABA

KW - ICS/LABA

KW - Cardiovascular safety

U2 - 10.1186/s12931-020-01398-w

DO - 10.1186/s12931-020-01398-w

M3 - Journal article

C2 - 32503599

VL - 21

JO - Respiratory Research (Print)

JF - Respiratory Research (Print)

SN - 1465-9921

ER -